# A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

> **NCT02998528** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 505 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Cisplatin
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT02998528
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-04
- **Primary completion:** 2021-09-08
- **Final completion:** 2024-12-06
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998528, "A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02998528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*